| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.19B | 6.05B | 6.34B | 5.94B | 5.41B | 4.71B |
| Gross Profit | 2.67B | 1.15B | 1.17B | 1.34B | 1.49B | 1.73B |
| EBITDA | 549.30M | 580.30M | 706.00M | 842.60M | 1.04B | 973.50M |
| Net Income | 185.20M | 194.60M | 263.70M | 371.10M | 618.20M | 616.90M |
Balance Sheet | ||||||
| Total Assets | 4.98B | 5.43B | 5.60B | 5.57B | 4.69B | 3.79B |
| Cash, Cash Equivalents and Short-Term Investments | 64.60M | 54.80M | 169.70M | 161.50M | 245.50M | 520.00M |
| Total Debt | 350.10M | 783.90M | 1.16B | 1.24B | 802.00M | 467.60M |
| Total Liabilities | 1.08B | 1.65B | 2.00B | 2.21B | 1.64B | 1.34B |
| Stockholders Equity | 3.90B | 3.78B | 3.60B | 3.35B | 3.04B | 2.45B |
Cash Flow | ||||||
| Free Cash Flow | 465.90M | 345.70M | 157.40M | -304.60M | -544.10M | 317.60M |
| Operating Cash Flow | 556.80M | 538.90M | 578.00M | 167.20M | 105.10M | 495.80M |
| Investing Cash Flow | -109.40M | -108.00M | -340.20M | -445.20M | -329.40M | -301.00M |
| Financing Cash Flow | -463.50M | -456.20M | -216.00M | 290.50M | 224.50M | -188.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹3.95B | 4.61 | ― | ― | 36.99% | 10.60% | |
65 Neutral | ₹2.63B | 14.07 | ― | 0.40% | 1.59% | -15.40% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
59 Neutral | ₹4.93B | 79.94 | ― | 0.74% | 6.79% | ― | |
56 Neutral | ₹1.78B | 12.89 | ― | 1.44% | 10.18% | 28.03% | |
53 Neutral | ₹767.28M | -5.21 | ― | 2.30% | -32.19% | -1097.08% | |
51 Neutral | ₹3.34B | -4.95 | ― | ― | -3.03% | 27.30% |
Sahyadri Industries Limited has announced that its trading window for dealing in the company’s securities will be closed from 1 January 2026 until 48 hours after the declaration of its financial results for the quarter and nine months ended 31 December 2025. The company has directed all designated persons and their immediate relatives to refrain from trading in its shares during this period, in line with SEBI’s Prohibition of Insider Trading Regulations, underscoring its adherence to regulatory norms and governance standards ahead of its upcoming financial disclosures.